Smarter prophylaxis: How RHD testing protects patients and resources
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Whitepaper
Discover the most effective approach for accurate CFTR gene analysis with our new whitepaper. Learn how laboratories can achieve superior variant detection and consistent coverage, while streamlining workflows and turnaround times.
This whitepaper explores the analytical and operational factors behind choosing targeted NGS for CFTR diagnosis. See how the Devyser CFTR assay delivers comprehensive variant coverage, integrated CNV detection, and rapid results in a single day workflow, helping laboratories deliver precise and reliable results with confidence.
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
Read More
Over the past decade, there has been a wealth of research investigating the ideal approach to RHD...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Read More